Energy-sparing by 2-methyl-2-thiazoline protects heart from ischaemia/reperfusion injury.
Masahiro NishiTakehiro OgataKo KobayakawaReiko KobayakawaTomohiko MatsuoCarlo Vittorio CannistraciShinya TomitaShunta TaminishiTakaomi SugaTomoya KitaniYusuke HiguchiAkira SakamotoYumika TsujiTomoyoshi SogaSatoaki MatobaPublished in: ESC heart failure (2021)
We identified the cardioprotective effect of systemically administered 2MT on cardiac I/R injury by sparing energy metabolism with reversible hypothermia. Our results highlight the potential of drug-induced hypothermia therapy as an adjunct to coronary intervention in severe ischaemic heart disease.
Keyphrases
- drug induced
- liver injury
- cardiac arrest
- robot assisted
- brain injury
- cerebral ischemia
- randomized controlled trial
- coronary artery disease
- coronary artery
- acute myocardial infarction
- heart failure
- left ventricular
- pulmonary hypertension
- adverse drug
- subarachnoid hemorrhage
- acute ischemic stroke
- human health
- minimally invasive
- stem cells
- early onset
- acute coronary syndrome
- aortic stenosis
- aortic valve
- climate change
- blood brain barrier
- transcatheter aortic valve replacement
- electronic health record